Search

BACKGROUND: Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness. METHODS We conducted a randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adult patients within 72 hours after the onset of mild Covid-19 symptoms. The primary end point was severe respiratory disease, defined as a respiratory rate of 30 breaths per minute or more, an oxygen saturation of less than 93% while the patient was breathing ambient air, or both. The trial was stopped early at 76% of its projected sample size because cases of Covid-19 in the trial region decreased considerably and steady enrollment of trial patients became virtually impossible. RESULTS A total of 160 patients underwent randomization. In the intention-to-treat population, severe respiratory disease developed in 13 of 80 patients (16%) who received convalescent plasma and 25 of 80 patients (31%) who received placebo (relative risk, 0.52; 95% confidence interval [CI], 0.29 to 0.94; P = 0.03), with a relative risk reduction of 48%. A modified intention-to-treat analysis that excluded 6 patients who had a primary end-point event before infusion of convalescent plasma or placebo showed a larger effect size (relative risk, 0.40; 95% CI, 0.20 to 0.81). No solicited adverse events were observed. CONCLUSIONS Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19. (Funded by the Bill and Melinda Gates Foundation and the Fundación INFANT Pandemic Fund; Dirección de Sangre y Medicina Transfusional del Ministerio de Salud number, PAEPCC19, Plataforma de Registro Informatizado de Investigaciones en Salud number, 1421, and ClinicalTrials.gov number, NCT04479163.). Fil: Libster, Romina Paula. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Pérez Marc, Gonzalo. Hospital Militar Central, Buenos Aires; Argentina Fil: Wappner, Diego. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Coviello, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Bianchi, Alejandra. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Braem, Virginia. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Esteban, Ignacio. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Caballero, Mauricio Tomás. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Wood, Cristian. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Berrueta, Mabel. Hospital Militar Central; Argentina Fil: Rondan, Aníbal. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Lescano, Gabriela Mariel. Hospital Dr. Carlos Bocalandro; Argentina Fil: Cruz, Pablo. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Ritou, Yvonne. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Fernández Viña, Valeria Silvina. Hospital Simplemente Evita; Argentina Fil: Álvarez Paggi, Damián Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Esperante, Sebastian. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigaciones Bioquímicas de Buenos Aires. Fundación Instituto Leloir. Instituto de Investigaciones Bioquímicas de Buenos Aires; Argentina Fil: Ferreti, Adrián. Hospital Dr. Carlos Bocalandro; Argentina Fil: Ofman, Gaston. University of Oklahoma; Estados Unidos Fil: Ciganda, Álvaro. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal Especializado de Agudos y Cronicos San Juan de Dios.; Argentina Fil: Rodriguez, Rocío. Hospital Simplemente Evita; Argentina Fil: Lantos, Jorge. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Valentini, Ricardo. No especifíca; Fil: Itcovici, Nicolás. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Hintze, Alejandra. No especifíca; Fil: Oyarvide, M. Laura. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Etchegaray, Candela. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Neira, Alejandra. Instituto de Efectividad Clínica y Sanitaria; Argentina Fil: Name, Ivonne. Instituto de Efectividad Clínica y Sanitaria; Argentina Fil: Alfonso, Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Swiss Medical Group; Argentina Fil: López Castelo, Rocío. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina Fil: Caruso, Gisela. Hospital Militar Central; Argentina Fil: Rapelius, Sofía. Hospital Militar Central; Argentina Fil: Alvez, Fernando. Hospital Militar Central; Argentina Fil: Etchenique, Federico. Hospital Militar Central; Argentina Fil: Dimase, Federico. Hospital Militar Central; Argentina Fil: Alvarez, Darío. Hospital Militar Central; Argentina Fil: Aranda, Sofía S.. Hospital Militar Central; Argentina Fil: Sánchez Yanotti, Clara Inés. Hospital Militar Central; Argentina Fil: De Luca, Julián. Hospital Militar Central; Argentina Fil: Jares Baglivo, Sofía. Hospital Militar Central; Argentina Fil: Laudanno, Sofía. Fundación Hematológica Sarmiento; Argentina Fil: Nowogrodzki, Florencia. Swiss Medical Group; Argentina Fil: Larrea, Ramiro. Hospital Municipal San Isidro; Argentina Fil: Silveyra, María. Hospital Militar Central; Argentina Fil: Leberzstein, Gabriel. No especifíca; Fil: Debonis, Alejandra. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Molinos, Juan. Fundación para la Investigación en Infectología Infantil; Argentina Fil: González, Miguel. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Perez, Eduardo. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Kreplak, Nicolás. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Pastor Argüello, Susana. Fundación para la Investigación en Infectología Infantil; Argentina Fil: Gibbons, Luz. Hospital Municipal de San Isidro; Argentina Fil: Althabe, Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto de Efectividad Clínica y Sanitaria; Argentina Fil: Bergel, Eduardo. Sanatorio Sagrado Corazón; Argentina Fil: Polack, Fernando Pedro. Provincia de Buenos Aires. Ministerio de Salud; Argentina

BackgroundTherapies to interrupt progression of early COVID-19 remain elusive. Among them, convalescent plasma in hospitalized patients was unsuccessful, perhaps because antibody should be administered earlier. We advanced plasma infusions to the first 72 hours of symptoms to arrest COVID-19 progression.MethodsA randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV2 in elderly subjects within 72 hours of mild COVID-19 symptoms. The primary endpoint was severe respiratory disease defined as a respiratory rate ≥30 and/or an O2satResults160 patients underwent randomization. In the intention-to-treat analysis (ITT), 13/80(16.2%) patients receiving plasma vs. 25/80(31.2%) receiving placebo experienced severe respiratory disease [RR(95%CI)= 0.52(0.29,0.94); p=0.026)] with an RRR=48%.A modified ITT analysis, excluding six subjects who experienced the primary endpoint before infusion, showed a larger effect size [RR(95%CI) = 0.40(0.20, 0.81), p=0.007]. High- and low-titer donor analyses, based on a median IgG titer=1:3,200, evidenced a dose-dependent response with an RRR=73.3% for recipients of high-titer plasma (p=0.016) and a number needed to treat (NNT)=4.4. All secondary endpoints exhibited trends towards protection. No solicited adverse events were observed.ConclusionsEarly administration of high-titer convalescent plasma against SARS-CoV2 to mildly ill infected seniors reduced COVID-19 progression. This safe, inexpensive, outpatient intervention facilitates access to treatment from industrialized to LMIC, can decompress demands on hospitals, and may contribute to save lives.Funded by The Bill & Melinda Gates Foundation and The Fundación INFANT Pandemic Fund. Registered in the Dirección de Sangre y Medicina Transfusional del Ministerio de Salud (PAEPCC19), Plataforma PRIISA (1421), and clinicaltrials.gov (NCT04479163).All authors have completed the ICMJE uniform disclosure form atwww.icmje.org/coi_disclosure.pdfand declare: no support from any organization for the submitted work; RL, GPM, DW and FPP are investigators in a phase 3 SARS CoV2 trial from Pfizer; no other relationships or activities that could appear to have influenced the submitted work.